Brokers Offer Predictions for Perspective Therapeutics, Inc.’s Q2 2024 Earnings (NYSE:CATX)

Perspective Therapeutics, Inc. (NYSE:CATX) – Research analysts at B. Riley lowered their Q2 2024 earnings per share estimates for Perspective Therapeutics in a research note issued to investors on Monday, July 1st. B. Riley analyst Y. Zhi now expects that the company will post earnings per share of ($0.21) for the quarter, down from their previous estimate of ($0.20). B. Riley has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($1.01) per share. B. Riley also issued estimates for Perspective Therapeutics’ Q3 2024 earnings at ($0.19) EPS, Q4 2024 earnings at ($0.21) EPS, FY2024 earnings at ($0.85) EPS and FY2025 earnings at ($1.01) EPS.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10. The business had revenue of $0.33 million during the quarter.

CATX has been the subject of a number of other research reports. Lifesci Capital reissued an “outperform” rating on shares of Perspective Therapeutics in a research report on Monday, May 6th. Royal Bank of Canada reissued an “outperform” rating and set a $30.00 price target on shares of Perspective Therapeutics in a research report on Friday, June 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research report on Tuesday, June 25th. Finally, Oppenheimer reissued an “outperform” rating on shares of Perspective Therapeutics in a research report on Tuesday, June 18th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $19.00.

Perspective Therapeutics Stock Performance

CATX stock opened at $10.49 on Wednesday. Perspective Therapeutics has a 12-month low of $2.05 and a 12-month high of $19.05. The company has a quick ratio of 12.98, a current ratio of 12.98 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. ZWJ Investment Counsel Inc. acquired a new stake in Perspective Therapeutics during the first quarter valued at approximately $26,000. Bleakley Financial Group LLC acquired a new stake in Perspective Therapeutics during the first quarter valued at approximately $40,000. Simplicity Wealth LLC acquired a new stake in Perspective Therapeutics during the first quarter valued at approximately $40,000. Taylor & Morgan Wealth Management LLC grew its holdings in shares of Perspective Therapeutics by 8.7% during the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after purchasing an additional 50,000 shares during the last quarter. Finally, RIA Advisory Group LLC grew its holdings in shares of Perspective Therapeutics by 1,313.4% during the first quarter. RIA Advisory Group LLC now owns 106,853 shares of the company’s stock valued at $127,000 after purchasing an additional 99,293 shares during the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Johan M. Spoor acquired 10,000 shares of Perspective Therapeutics stock in a transaction on Thursday, June 13th. The shares were bought at an average price of $11.70 per share, for a total transaction of $117,000.00. Following the completion of the purchase, the chief executive officer now directly owns 13,757 shares in the company, valued at approximately $160,956.90. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Perspective Therapeutics news, CEO Johan M. Spoor purchased 10,000 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The shares were acquired at an average price of $11.70 per share, for a total transaction of $117,000.00. Following the completion of the purchase, the chief executive officer now owns 13,757 shares in the company, valued at approximately $160,956.90. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Lori A. Woods purchased 4,587 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was acquired at an average price of $10.90 per share, for a total transaction of $49,998.30. Following the purchase, the director now owns 159,985 shares of the company’s stock, valued at approximately $1,743,836.50. The disclosure for this purchase can be found here. Insiders have purchased a total of 30,814 shares of company stock worth $385,487 over the last quarter. 3.52% of the stock is owned by corporate insiders.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.